We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
ASX edges down in a quiet market Pilbara Minerals falls 5pc as share block sale is reported We...
Read ArticleIsland Pharmaceuticals undertakes a $3.5m capital raise strongly supported by cornerstone investors...
Read ArticleBig biotech names support Island Therapeutics raising Radiopharm eyes FDA approval to start a thera...
Read ArticleHealthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as...
Read ArticleStockhead joined with IR Department and Morgans for HealthInvest 2024 in Sydney last week The event...
Read ArticleASX health stocks dropped 1.74% in the past five days, while the broader markets rose 1.55% Power c...
Read ArticleASX health stocks dropped 1.22% in the past four days, while the broader markets fell 1.35% Morgans...
Read ArticleStockhead’s Fraser Palamara sits down with new Race Oncology (ASX:RAC) executive chair Dr Peter Smit...
Read ArticleASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing;...
Read ArticleRace Oncology hails significant FY24 with several key milestones achieved First batch of (cGMP) man...
Read ArticleAussie stocks dropped despite Wall Street edging up ahead of Nvidia’s report Inflation eased to 3.5...
Read ArticleThe ASX200 closed down 0.17% at 8,071 points as the market awaits local inflation data for July tomo...
Read ArticleASX healthcare stocks showed mixed results following the release of their most recent financials on...
Read ArticleStockhead joins with IR Department and Morgans for HealthInvest 2024 in Sydney in September Event t...
Read ArticleS&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expec...
Read ArticleStockhead’s Sarah Hughan sits down with Race Oncology’s (ASX:RAC) CEO Dr Daniel Tillett to get the s...
Read ArticleThe EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-l...
Read ArticleASX healthcare shares are in the red on Tuesday, with the S&P/ASX 200 Health Care Index (ASX: XH...
Read ArticleA2 Milk Company Ltd (ASX: A2M) shares ended up having a stellar finish to the year in FY24. In t...
Read ArticleThe 2024 Bioshares Biotech Summit being held in Fremantle from July 12-13 Morgans says conference l...
Read ArticleA2 Milk Co Ltd (ASX: A2M) shares are in the green today. Shares in the S&P/ASX 200 Index (ASX...
Read ArticleThe ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biot...
Read ArticleTax-loss selling could be pile-driving fundamentally good companies into the ground. At least, that'...
Read ArticleRace Oncology says non-clinical toxicology and safety studies of lead drug RC220 Bisantrene succe...
Read ArticleCleo commences FDA process Cleo Diagnostics (ASX:COV) has announced significant progress in advancin...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a tough time on Wednesday after a stronger than expec...
Read ArticleAfter closing up 1.4% on Tuesday, the S&P/ASX 200 Index (ASX: XJO) looks ready to give back mos...
Read ArticleRace Oncology Ltd (ASX: RAC) shares burst out of the gates on Wednesday morning. In early trade, the...
Read ArticleFor biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The...
Read ArticleWith the S&P/ASX 200 Health Care Index (ASX: XHJ) dipping slightly into the red on Wednesday, it...
Read ArticleS&P/ASX 200 Index (ASX: XJO) gold stocks enjoyed a blistering rally from late February through...
Read ArticleThe ASX 200 has finished the day up a per cent, after interest rates were kept on hold at 4.35%, fir...
Read ArticleASX rose as the RBA held interest rates at 12-year high 4.35pc All 11 sectors on the ASX gained, w...
Read ArticleUS FDA extends Rare Paediatric Disease Designation (RPDD) to Race Oncology’s novel RC220 bisantrene...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is back on form on Tuesday and storming higher. In afternoon t...
Read ArticleRace Oncology Ltd (ASX: RAC) shares are roaring higher on Tuesday morning. In early trade, the ASX h...
Read ArticleRace Oncology (ASX:RAC) has announced that the US FDA has extended Rare Paediatric Disease D...
Read ArticleRace Oncology (ASX:RAC) has announced a preclinical breakthrough in heart toxicity side effects caus...
Read ArticleRace Oncology (ASX:RAC) has reported the results of preclinical work performed under contrac...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) endured a...
Read ArticleAussie shares slipped over 1pc after the King’s Birthday long weekend Mining and Real Estate sector...
Read ArticleUS FDA extends orphan drug designation to Race’s re-formulated RC220 bisantrene drug product for...
Read ArticleThis article was originally published on Fool.com. All figures quoted in US dollars unless otherwis...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a very tough start to the week. In afternoon trade,...
Read ArticleOrthocell (ASX:OCC) has taken a significant step forward in its efforts to introduce its SmrtGraft p...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is down 1.1% today, but you can't blame this rocketing ASX 200...
Read ArticleRace Oncology (ASX: RAC) has achieved a significant breakthrough with the US Food and Drug Administr...
Read ArticleDeciding which ASX dividend shares to buy can be a gruelling process. Luckily for income investors,...
Read ArticleInvestors tend to consider ASX 200 bank shares as dividend payers rather than growth investments, wi...
Read ArticleThe work of pharmaceutical companies can bring new hope to patients delivering solutions to unmet me...
Read ArticleResearch shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase th...
Read ArticleInvestors that are on the lookout for some big returns might want to check out these ASX 200 shares...
Read ArticleThe conventional wisdom on the ASX exchange-traded fund (ETF) landscape is that index funds offer in...
Read ArticleThe ASX200 closed the day down 0.3 of a per cent. Aside from consumer discretionary and healthcar...
Read ArticleASX retreats on Tuesday ahead of Fed Budget and US PPI/CPI Copper stocks up after the metal hit hig...
Read ArticleG'day Treasurer, I'm glad I've caught you in time. I know you have a Budget to hand down in a few ho...
Read ArticleBisantrene and decitabine used together offer significantly improved cancer cell-killing across 143...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a tough session on Tuesday. In afternoon trade, the...
Read ArticleThe ASX200 is tracking lower than expected, down nearly a quarter of a per cent. The health care...
Read ArticleASX healthcare shares are one of only two market sectors trading in the green at the time of writing...
Read ArticleOne of my personal investing mottos is "the market is straight up kooky dooks". Not only did I think...
Read ArticleRace Oncology says bisantrene + decitabine effective Race Oncology (ASX:RAC) jumped 8% this morning...
Read ArticleS&P/ASX 200 Index (ASX: XJO) stock GUD Holdings Ltd (ASX: GUD) is off to the races on Tuesday....
Read ArticleRace Oncology (ASX:RAC) has shared the results from recent preclinical work performed under...
Read ArticleRace Oncology (ASX:RAC) had caught the eyes of HotCopper users pre-market on Tuesday as the company...
Read ArticleRace Oncology (ASX:RAC) had caught the eyes of HotCopper users pre-market on Tuesday as the company...
Read ArticleASX Health sector was in correction territory in April Why is the health sector different from othe...
Read ArticleThere’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to c...
Read ArticleSeveral ASX companies are repurposing or resurrecting abandoned or under utilised drugs Paradigm B...
Read ArticleBy Tim Boreham ASX code: Race Oncology ((RAC)) Shares on issue: 164,778,179 Market cap: $237.3m Fina...
Read ArticleWhat is traditional chemotherapy? How is Race Oncology trying to change it? What are the alternative...
Read ArticleRace Oncology says certificate of analysis issued by Ardena for first cGMP batch of bisantrene form...
Read ArticleThe ASX200 closed the day down .4 of a per cent, with IT stocks weighing on the market and energy le...
Read ArticleThe ASX 200 slipped by -0.3% on Tuesday, tracking movements on Wall Street overnight. The local mar...
Read ArticleRace Oncology (ASX: RAC) has made further progress in the development of its proprietary bisantrene...
Read ArticleRace Oncology (ASX:RAC) has announced that a Certificate of Analysis has been issued for the...
Read ArticleMineral Resources (MIN) has updated on the Lockyer-5 gas well. The Kingia Sandstone target downho...
Read ArticleRace Oncology Ltd (ASX: RAC) shares are on form and racing higher on Monday. In afternoon trade, th...
Read ArticleLocal markets end lower on big bank sell-off Material gains offset by Telco’s and Financials Small...
Read ArticleRace Oncology appoints Associate Professor Erin Howden to scientific advisory board Howden has rese...
Read ArticleASX looks set rise after mixed session on Wall street overnight Momentum in the tech sector wanes;...
Read ArticleIt’s been a tough couple of years for ASX health care with challenging economic conditions including...
Read ArticleASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essenti...
Read ArticleThe ASX200’s been trading down a quarter of a per cent – even further than expected. The utiliti...
Read ArticleAtomo jumps 90pc after reporting a significant sales order AdAlta up 20pc after revealing key resu...
Read ArticleRace Oncology reports an apparent step forward in finding treatment for Acute Myeloid Leukemia Ra...
Read ArticleThe ASX200 is set to fall with futures down -0.13% near 8.30am AEDT on Wednesday. The US markets...
Read ArticleViking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
Read ArticleEarly detection and effective treatment can lead to remission or cure for many cancers Optiscan’s t...
Read ArticleLeading cardiologist says bisantrene has potential to significantly change cancer treatment landsca...
Read ArticleBiotech doesn’t need another pandemic for a resurgence – it’s made a strong comeback regardless. Sto...
Read ArticleThe Lake Resources N.L. (ASX: LKE) share price fell to a new 52-week low of 13 cents on Thursday....
Read ArticleAustralian company Race Oncology (ASX:RAC) has announced the appointment of Dr Daniel Tillet...
Read ArticleRace Oncology appoints former chief scientific officer and executive director Dr Daniel Tillet as C...
Read ArticleDr Daniel Tillett steps into the role of CEO at Race Oncology (ASX:RAC), bringing with him more than...
Read ArticleASX to open slightly lower after a retreat on Wall Street Fed officials said they are open to more...
Read ArticleASX futures were down 0.06 per cent near 8:30 am AEDT, implying the ASX will dip slightly into the r...
Read ArticleLake Resources N.L. (ASX: LKE) shares had a subdued finish to the week. The lithium developer's sha...
Read ArticleThe Lake Resources Ltd (ASX: LKE) share price has been under intense pressure over the last year. A...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleThe good news for income investors is that there are a good number of quality ASX dividend stocks t...
Read ArticleSYDNEY, Nov. 14, 2023 /PRNewswire/ — HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased...
Read ArticleThe Australian share market is a great place to generate a passive income. And while it may take ti...
Read ArticleThe Pro Medicus Ltd (ASX: PME) share price has spiked well above $86 in Monday trading amid investo...
Read ArticleASX shares that have fallen hard but have a compelling future could be good opportunities if they'r...
Read ArticleThe Australian share market is a great place to generate a passive income. That's because it is hom...
Read ArticleStockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might h...
Read ArticleIt's been a strong session for the All Ordinaries Index (ASX: XAO) and most ASX All Ords shares so...
Read ArticleWelcome to Thursday. The ASX is set to rise with ASX200 futures being 28pts higher (up 0.40 per cent...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline....
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price is catching the eye on Tuesday. In morning trade, the...
Read ArticleNow could be the time to pounce on Universal Store Holdings Ltd (ASX: UNI) shares. That's the view...
Read ArticleASX200 closes +1.13% higher Property stocks, Industrials and IT Sector gain more than 2% Small caps...
Read ArticleNews relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD f...
Read ArticleThe ASX200 performed consistently holding at about .4 of a per cent up throughout the day. IT was...
Read ArticleThe ASX200 is up point four of a per cent so far today, despite significant falls for the energy sec...
Read ArticleRace Oncology (ASX:RAC) completes a series of preclinical animal and laboratory studies using its no...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price is having a very strong session. In morning trade, the...
Read ArticleRace Oncology (ASX:RAC) has announced that Laurus Labs (has successfully produced its first...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleRace Oncology (ASX:RAC) produces its first batch of bisantrene dihydrochloride under cGMP standards...
Read ArticleStockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might h...
Read ArticleRace Oncology (RAC) has shown once again that a combination of bisantrene with other chemodrugs lead...
Read ArticleThe market may be falling for a fourth day in a row, but that hasn't stopped a couple of ASX health...
Read ArticleAccording to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleEarnings reports dominated headlines in August Despite solid results from ASX healthcare giants, th...
Read ArticleThe S&P ASX 200 was down 0.73% in August with mid caps and small caps down 1.3% for the month E...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleRace Oncology (RAC) announces that Dr Peter Smith assumes the role of Executive Director following D...
Read ArticleBiotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two g...
Read ArticleMoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and...
Read ArticleASX benchmark falls 0.86% for the day, dragged down by bad news from China. Telcos, Energy and Inf...
Read ArticleRace Oncolocy’s new corporate strategy has been designed to maximise the inherent value of its core...
Read ArticleRecce Pharma surges 20pc on anecdotal results Emyria launches a ketamine-assisted therapy (KAT) pro...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticleRace Oncology (RAC) receives an additional $1.66 million in an R&D Tax Incentive Refund from the...
Read ArticleRace Oncology executes agreement with leading global contract development and manufacturing organis...
Read ArticleRace Oncology (RAC) partners with Ardena to bolster the manufacturing capabilities of its flagship i...
Read ArticleRace executes worldwide license agreement with City of Hope, one of the largest cancer research and...
Read ArticleRace executes worldwide license agreement with City of Hope, one of the largest cancer research and...
Read ArticleBod Science provided a ‘landmark update’ on its Phase IIB insomnia clinical trial Neurotech receive...
Read ArticleThe ASX is expected to kick off the week on a positive after last week’s tumble on Wall Street, whic...
Read ArticleBrisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “gam...
Read ArticleSmall cap health stocks are not known to pay dividends But there’s a handful of such stocks on the...
Read ArticleOrphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an e...
Read ArticleIâm about to tell you about some excellent All Ordinaries (ASX: XAO), or All Ords, ASX shares tha...
Read ArticleArtificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discove...
Read ArticleIf youâre looking to take advantage of recent weakness in the lithium industry to make some inves...
Read ArticleA key part of the Australian economy is the mining sector. In light of this, it will come as little...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) ended the week on a high, rising 0.51% to finish the session a...
Read ArticleS&P/ASX 200 Index (ASX: XJO) gold shares are enjoying some healthy tailwinds from a fast-risin...
Read ArticleThe materials sector has recovered to make a slight gain this morning, as the impact of the now-cate...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positiv...
Read ArticleRace Oncology (RAC) flags the multi-billion-dollar market potential of its Zantrene drug as a potent...
Read ArticleThe IGO Ltd (ASX: IGO) share price is besting the benchmark S&P/ASX 200 Index (ASX: XJO) on Fri...
Read ArticleS&P/ASX 200 Index (ASX: XJO) gold shares are charging higher today. In morning trade on Wednesd...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) lifted higher on Tuesday, rising 0.18% to close at 7,236 point...
Read ArticleIt’s starting to feel like a while since the beaten-up ASX share BWX Ltd (ASX: BWX) has been availa...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having a subdued session ahead of the RBA meeting. In aft...
Read ArticleThe All Ordinaries Index (ASX: XAO) is in the red today â just. The benchmark is down 0.07% right...
Read ArticleParadigm Biopharma demonstrates efficacy of knee osteoarthritis drug Race Oncology released a third...
Read ArticleRace Oncology (ASX:RAC) has updated investors with market research commissioned to better un...
Read ArticleBenchmark set to finish close to flat as Energy stocks slump again Goldies are surging again, with...
Read ArticleWith so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a sm...
Read ArticleAnother week, another bank collapse? Hopefully not this week⦠weâve had enough of those, thank...
Read ArticleThe Little Green Pharma Ltd (ASX: LGP) share price is smokin’ hot today, up 13.2% to 22 cents on ne...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is having another red day on Friday. In afternoon trade, the...
Read ArticleThe share price of All Ordinaries Index (ASX: XAO) healthcare company Race Oncology Ltd (ASX: RAC)...
Read ArticleStockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleThe Block Inc (ASX: SQ2) share price is on course to end the week on a very disappointing note. In...
Read ArticleThe ASX is expected to open lower once again on Friday after the Bank of England followed in the US...
Read ArticleBenchmark skips happily to an 0.87% rise for the day. Energy stacks on 4.5% while the techies recov...
Read ArticleBenchmark skips happily to an 0.87% rise for the day. Energy stacks on 4.5% while the techies recov...
Read ArticleThe S&P/ASX 300 index may be trading notably lower than its recent highs, but that hasnât sto...
Read ArticleThe Neuren Pharmaceuticals Ltd (ASX: NEU) share price is racing higher again on Wednesday. In morni...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) is out of form again on Tuesday. In afternoon trade, the bench...
Read ArticleWell, it’s another day, another fall for the S&P/ASX 200 Index (ASX: XJO) so far this Tuesday....
Read ArticleIt’s been a fairly awful start to the week for ASX shares and the S&P/ASX 200 Index (ASX: XJO)...
Read ArticleRace Oncology (RAC) executes a number of contracts to begin an observational cardioprotection breast...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has started the week in a subdued fashion. At the time of wri...
Read ArticleOverall, it’s been a pretty negative day for the S&P/ASX 200 Index (ASX: XJO) and ASX shares so...
Read ArticleNeuren Pharma gets a ‘historic’ FDA approval for DAYBUE to treat Rett syndrome Genetic Technologies...
Read ArticleRace Oncology (RAC) launches a new collaborative research project to uncover how its Zantrene produc...
Read ArticleIt’s an exciting time for Race Oncology investors as the company appoints a new CEO and presses forw...
Read ArticleThe FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have g...
Read ArticleRace Oncology (RAC) receives human ethics approval for the next stage of its clinical trial of Zantr...
Read ArticleASX investors love to see the insiders of companies they have shares in putting their money where t...
Read ArticleJapanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based devic...
Read ArticleWhen a company director buys up 25,000 of their own company’s shares, it’s certainly an event to ta...
Read ArticleRace Oncology has announced the appointment of Damian Clarke-Bruce as its managing director...
Read ArticleRace Oncology (RAC) appoints Damian Clarke-Bruce as Managing Director and Chief Executive Officer, e...
Read ArticleClarity Pharma announced positive results from Phase 1 trial Starpharma brings VIRALEZE to Indonesi...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleRace Oncology received positive feedback from the US FDA HeraMed launches HeraCARE in Victoria Meso...
Read ArticleIt’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodge...
Read ArticleWe take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks fr...
Read ArticleIt’s Tuesday afternoon, and after a long, hard day buying and selling bits of paper that say you own...
Read ArticleDaniel Tillet of Race Oncology (RAC) speaks at the Switzer Small and Micro Cap Investor Strategy Day...
Read ArticleSpecial Report: A new breakthrough formulation for Race Oncology’s lead asset drug Zantrene means it...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleHealthcare is one of those industries that enjoys relatively stable demand through tougher economic...
Read ArticleWhitehaven Coal Ltd (ASX: WHC) shares are having a roller coaster day today. The coal producer’s s...
Read ArticleThere’s no getting away from the fact that it has been a difficult year for investors. Since the sta...
Read ArticleThe Cogstate Limited (ASX: CGS) share price has continued its ascent on Thursday. In morning trade,...
Read ArticleAfter a promising start to Wednesday’s trade, the S&P/ASX 200 Index (ASX: XJO) handed back its...
Read ArticleWednesday morning saw healthcare stock Race Oncology [ASX:RAC], developer of cancer drug treatments...
Read ArticleThe S&P/ASX 200 Index (ASX: XJO) has resumed its downward trend on Wednesday. In afternoon trad...
Read ArticleThe Whitehaven Coal Ltd (ASX: WHC) share price has been a big performer for shareholders in 2022. W...
Read ArticleASX coal shares opened strongly on Wednesday, with the share prices of the biggest players surging....
Read ArticleRace Oncology (RAC) develops a new and improved formulation of its Zantrene product that enables per...
Read ArticleBenchmark rises early, wobbles late, gains 0.4% Small caps all over the shop today, up 0.9% Metals...
Read ArticlePYC Therapeutics and Race Oncology announce new RNA programs Recce Pharma accelerates its clinical...
Read ArticleMonday was not the start to the week that investors were probably hoping for. By the time the closi...
Read ArticleRace Oncology’s lead asset drug Zantrene has shown that it is effective in reducing the risk of hear...
Read ArticleRace Oncology (RAC) advanced studies of its cancer-treating drug, Zantrene over the June quarter Th...
Read ArticleUS FDA approves the first clinical trial using naturally derived psychedelic drugs It could open po...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price had yet another stunning day, leaving the broader in...
Read ArticleASX renewable energy shares incorporate a range of companies involved in producing clean energy sou...
Read ArticleShareCafeEvening Report: 30 June, 2022 by Melissa Darmawan The Australian sharemarket closed at se...
Read ArticleA number of ASX shares in the S&P/ASX 200 Health Care Index (ASX: XHJ) outperformed the broad...
Read ArticleShareCafeLunch Report: 30 June, 2022 by Melissa Darmawan The Australian sharemarket has fallen for...
Read Article30 Jun 2022 - A snapshot of the stocks on the move featuring, Paradigm Biopharmaceuticals (ASX:PAR),...
Read ArticleThis article was originally published on Fool.com. All figures quoted in US dollars unless otherwise...
Read ArticleThe Cann Group Ltd (ASX: CAN) share price is rocketing on Thursday. This comes after the cannabis c...
Read ArticleRace Oncology (RAC) announces its Zantrene product can protect mice hearts from permanent damage ca...
Read ArticleCann Group’s Mildura facility has been granted GMP licence Paradigm receives patent application acc...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price is surging today on anti-cancer drug news. Shares in...
Read ArticleRace Oncology (RAC) releases positive final results from a preclinical research program exploring t...
Read ArticleThe Australian share market is home to a good number of shares that have the potential to grow stro...
Read ArticleRace Oncology demonstrates positive results in melanoma therapy HITIQ extends deal with NZ Rugby Ar...
Read ArticleInterim results from a Race Oncology (RAC) preclinical research program show its Zantrene drug has...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price flew higher today following a positive announcement by...
Read ArticleShareCafeEvening Report: 9 June, 2022 by Melissa Darmawan The Australian sharemarket fell to a fou...
Read ArticleBenchmark and small cap index down hard Life on the indices can be hard, unless your in energy, pos...
Read ArticleShareCafeLunch Report: 9 June, 2022 by Melissa Darmawan The major banks weigh on the Australian sh...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price is surging today after the specialty pharmaceutical co...
Read Article09 Jun 2022 - A snapshot of the stocks on the move featuring, Charger Metals (ASX:CHR) and Lithium A...
Read ArticleRace Oncology (RAC) has launched an on-market share buyback program to purchase up to four million...
Read ArticleHighlights Race Oncology expands its clinical trial in EMD AML and MDS across five new sites in...
Read ArticleRace Oncology (RAC) is set to expand its BISECT cancer trial for its Zantrene product to include fi...
Read ArticleRace Oncology expands its Phase 1b/2a clinical trial of Zantrene to Europe Nova Eye roll out iTrack...
Read ArticleCancer treatment company Race Oncology (RAC) comes out of a trading halt to announce the completion...
Read ArticleHighlights Race Oncology has received encouraging results from the first-stage trial of Zantrene...
Read ArticleRace Oncology completed dosing stage of Phase, eyes Phase 2 trial Immutep presents trials data at A...
Read ArticleBoth ASX Small Cap and benchmark index are down about 0.5% A bleak forecast from Covid-stricken Chi...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price edged higher before being frozen today. This comes aft...
Read ArticleHighlights: Race Oncology is riding high with governance approval for human trial of its new the...
Read ArticleRace Oncology (RAC) receives governance approval for a clinical trial of Zantrene in patients with...
Read ArticleRace Oncology is set to commence Phase 1 study of Zantrene after being given governance approval Rh...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleRace Oncology (ASX:RAC) has received human ethics approval for its open-label clinical trial...
Read ArticleThe ASX200 has taken a 0.5% hit on Wednesday, with the tech sector giving back all the previous sess...
Read ArticleRace Oncology (RAC) receives human ethics approval for its clinical trial of Zantrene in patients w...
Read ArticleBiotech sector has had a tough time recently But there are signs of things improving this year A lo...
Read ArticleRace Oncology (ASX:RAC) has shared the interim results from the extramedullary acute myeloid...
Read ArticleRace Oncology (RAC) is rapidly advancing its cancer drug as a possible new treatment option for pat...
Read ArticleRace Oncology (ASX:RAC) has shared the final results from the clear cell renal cell carcinom...
Read ArticleShares in Race Oncology Ltd (ASX: RAC) are soaring and trading 5% in the green at $2.77 apiece. At...
Read ArticleRace Oncology (RAC) has revealed its Zantrene product can kill a range of kidney cancer cells both...
Read Article“Advanced kidney cancer has a large unmet need for improved treatment options and Zantrene in combin...
Read ArticleShares in Race Oncology Ltd (ASX: RAC) soaring today to finish trading 14% higher in the green. Th...
Read ArticleToday wasn’t a great day for most ASX shares. The All Ordinaries Index (ASX: XAO) ended up losing 0...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticleRace Oncology (ASX: RAC) has announced the publication of a peer-reviewed preclinical study that has...
Read ArticleRace Oncology (RAC) announces its lead Zantrene drug has been found to show synergy with several ot...
Read ArticleInoviq (ASX:IIQ) has been granted a Brazilian patent covering the use of BARD1 isoforms in lung and...
Read Article“This work provides further preclinical data to support our upcoming Phase 1b/2 extramedullary AML t...
Read ArticleThey say if you can’t measure it, you can’t manage it – and that holds particularly true when it com...
Read ArticleDisclosure: The authors of this article and owners of Next Investors, S3 Consortium Pty Ltd, and ass...
Read ArticleThe ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial t...
Read ArticleRace Oncology (ASX: RAC) executive director and entrepreneur Dr Daniel Tillett has joined smart ener...
Read ArticleThe ASX200 has vacillated all of Monday in a whiny, unattractive way for a major global index. Like...
Read ArticleChristina Manfre, a partner at PKF Sydney, will provide leadership to Race Oncology’s financial anal...
Read ArticleRace Oncology (RAC) reports $1.8 million in cash outflows for the quarter, an increase from the $93...
Read ArticleKey points The Race Oncology share price is up as high as 2.8% today A new discovery relating to...
Read ArticleKey points Firebrick Pharma will debut on the ASX at 12:30pm AEDT today The company is developing...
Read Article“The increased refund for FY21 is representative of the enhanced investment we made into R&D as...
Read ArticleReturns in the ASX healthcare basket were fairly robust throughout 2021. Sector earnings saw a retu...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read Article“The number of applications reflects enthusiasm for the significant potential of our lead drug Zantr...
Read ArticleRace Oncology (ASX: RAC) is closing out 2021 with an extra $29.7 million in the bank after completin...
Read ArticleRace Oncology (RAC) raises $29.7 million in an oversubscribed share purchase plan The company recei...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price is climbing today on the back of the company’s latest...
Read ArticleAfter identifying its heart protective effects, Race Oncology (ASX: RAC) has extended the collaborat...
Read ArticleThis strategically important collaboration will underpin a cardio-protective Phase 2b clinical trial...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read ArticleClinical stage RNA focused company targeting multiple cancer indications with estimated annual oncol...
Read Article“Zantrene is the first anti-cancer agent that we have found to exhibit a cardioprotective profile wh...
Read ArticleSpecialty pharmaceutical company Race Oncology (ASX: RAC) has found its lead candidate Zantrene (bis...
Read ArticleRace Oncology (RAC) confirms Zantrene can protect heart muscle cells from carfilzomib-induced cell...
Read ArticlePrecision oncology company Race Oncology (ASX: RAC) is looking to raise capital to enable the execut...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticleThe ASX drifted sideways on Wednesday, as uncertainty continues to linger around the outlook for mon...
Read ArticleInvestors are selling off shares in precision oncology company Race Oncology Ltd (ASX: RAC) after a...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has just dropped into the red. At the time...
Read ArticleStockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) per...
Read ArticleHighlights As per experts, the global cancer drug market is likely to accelerate in the upcoming...
Read ArticleThe Australian bourse recouped most of yesterday’s losses despite tech stocks dropping again, this t...
Read ArticleCancer biotech Race Oncology is tapping its base of loyal retail shareholders for a fresh capital ra...
Read ArticleThe company said this is the first time a drug has demonstrated the ability to both target t...
Read ArticleShares in Australian pharmaceutical company Race Oncology Ltd (ASX: RAC) jumped higher today and fi...
Read ArticleRace Oncology’s drug Zantrene shown to protect human heart muscle cells from anthracycline-induced...
Read ArticleThe ASX 200 Health Index (XHJ) is down by 0.35% at the time of writing, compared to the broader inde...
Read ArticleInterim research results has found Race Oncology’s (RAC) Zantrene drug can protect heart muscles fr...
Read ArticleRace Oncology (RAC) joins forces with the University of Wollongong (UOW) for a preclinical evaluati...
Read ArticleThe ASX 200 Health Index (XHJ) is up by 0.57% at the time of writing, compared to the broader index...
Read ArticleShares in Australian pharmaceutical company Race Oncology Ltd (ASX: RAC) are up 4% from the open to...
Read ArticleRace Oncology (RAC) reports a slight decrease in cash and equivalents to $8.94 million as of 30 Sep...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price is edging lower today despite a positive development b...
Read ArticleJust like yesterday the ASX rallied for most of the day but retreated in the afternoon and today clo...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price has been seesawing today and is now at $3.17. That’s a...
Read ArticleRace Oncology (RAC) is granted its sixth US patent for its cancer drug, Zantrene, valid until July...
Read ArticleRace Oncology (ASX:RAC) has announced it has been issued a new patent from the US Patent and...
Read ArticleHighlights Magellan Financial Group shares dropped over 7% after it reported a drop in its FUM...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price has been a positive performer on Wednesday. In morning...
Read ArticleRace Oncology (ASX:RAC) has shared interim results from its collaborative preclinical melano...
Read ArticleThe ASX finished September on a solid note but not enough to avoid the worst month since March 2020....
Read ArticleZantrene® at low concentrations kills high FTO producing melanoma cancer cells Sensitivity to Zant...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price jumped out of the starting blocks today, shooting up 7...
Read ArticleOur new business model is to research, analyse, and invest in up and coming small cap ASX-listed bio...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price has soared into the green this past month, and now tra...
Read ArticleIn the past fortnight there were nearly four dozen directors on the ASX who bought or sold shares in...
Read ArticleAlthough earnings results were the main theme in August, there were also some notable healthcare bre...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticleRace Oncology (ASX:RAC) has announced that the first patient has been dosed in the Phase 1b/...
Read ArticleDespite a solid start to the day the ASX closed Monday at the same point it closed on Friday. After...
Read ArticleSummary Nutritional Growth Solutions has entered into a non-exclusive supply agreement to launch...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price is swinging from losses to gains to losses again. At t...
Read ArticleThe ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price finished in the red today. The dip came after Race upd...
Read ArticleThe ASX200 chalked up another day of gains in Thursday trade, and once again it was resources leadin...
Read ArticleAfter a rough couple of days, local stocks got back in the saddle on Wednesday as most large cap sec...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleMost ASX large cap sectors finished in the red today, in a topsy-turvy session which saw the ASX200...
Read ArticleHealthcare is a constantly changing industry in which you may be asking yourself if your investment...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleIn FY21 the ASX 200 returned over 20 per cent but the 100 best performing ASX stocks all gained over...
Read ArticlePlenty of action on the biotech front today has provided ASX investors with some mouth-watering gain...
Read ArticleThe ASX has gained nearly 1.5 per cent per cent today, rebounding from a big Monday selloff. Once ag...
Read ArticleShareCafeHidden Gems Webinar Recap: RAC, IMU, AUA & BRN Catch up on the full webinar with pres...
Read ArticleShareCafeA precision oncology company Race Oncology (ASX: RAC) – Hidden Gems Webinar. Presenter – D...
Read ArticleSummary Race Oncology has entered into an agreement with Trialog Clinical Trials to support its...
Read ArticleThere’s no two ways about it, melanoma kills, especially here in Australia. We have one of the highe...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has ret...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price is falling today after the pharmaceutical company anno...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price has been a positive performer on Wednesday. In morning...
Read ArticleIt was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies relea...
Read ArticleRisk on sentiment returned to the ASX following yesterday’s 1.9 per cent drop. The ASX 200 closed 1....
Read ArticleRace Oncology (ASX:RAC) has announced the appointment of Professor Michael Kelso as its prin...
Read ArticleRace Oncology (ASX:RAC) has announced that a team of researchers have identified a number of...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleRace Oncology (ASX:RAC) says it has received binding commitments to raise $5.4 million befor...
Read ArticleThe Cancer fighting biotech company Race Oncology Ltd [ASX:RAC] share price is up 4.23% today. Risi...
Read ArticleSummary The ASX 200 crosses 7100 mark, its 14-month highest level since the coronavirus pandemic...
Read ArticleSummary Neurotech International has commenced Phase I/II open-label clinical trial in children h...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At t...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price is gaining today, up 5% in late morning trade. The ASX...
Read ArticleOn a day the ASX finished nearly 0.5 per cent up, tech stood alone in the red losing more than 2 per...
Read ArticleToday we will take a look at why we like Race Oncology (ASX RAC). Race Oncology (ASX RAC) is a preci...
Read ArticleAfter gaining 0.5 per cent in the first hour of trade the ASX only finished slightly upwards. The AS...
Read ArticleRace Oncology Ltd (ASX: RAC) shares are in a trading halt today as the company seeks to raise an un...
Read ArticleSummary 5G Networks reported robust growth across all three core products in Q3 FY21 and witness...
Read ArticleSummary Oventus Medical witnessed growth in booked revenue and acceleration in telehealth bookin...
Read ArticleSummary Race Oncology Limited has entered into a collaboration for the preclinical study of its...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price is climbing today after an update from the Aussie heal...
Read ArticleSummary Medicinal cannabis player MGC Pharmaceuticals has a historic quarter with the ground-bre...
Read ArticleSummary Exopharm obtained firm commitments from institutional and sophisticated investors to rai...
Read ArticleRace Oncology (ASX:RAC) has announced the appointment of Dr David Fuller as its chief medica...
Read ArticleIt was another day in the green for the ASX as it edged closer to surpassing the record high it reac...
Read ArticleIn afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and edging slightly lower....
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price has been a very strong performer on Thursday. In morni...
Read ArticleAnother day, another IPO – today the new listee was biotech Island Pharmaceuticals (ASX:ILA). Island...
Read ArticleUranium explorer 92 Energy (ASX:92E) is among several companies lined up to list on the ASX this or...
Read ArticleClosing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike....
Read ArticleIn afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on course to end the shortened week with...
Read ArticleSource:WHYFRAME, Shutterstock Summary Huge market volatility has been observed in 2021 so far a...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price is struggling in early-morning trade despite the compa...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThe ASX finished the day slightly in the green, dragged down by tech stocks which lost nearly 1.5 pe...
Read ArticleSource: Tyler Olson, Shutterstock Summary ASX-listed oncology player Race Oncology to explore t...
Read ArticleRace Oncology Ltd (ASX: RAC) shares are slipping in late morning trade despite the company providin...
Read ArticleOn this day last year, global stocks capped off a historic one-month collapse with another epic fall...
Read ArticleSource: Blue Planet Studio, Shutterstock Summary Oncology player Race Oncology has collaborated...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price is sliding today, despite the announcement of a new pr...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks f...
Read ArticleSource: fizkes ,Shutterstock Summary Race Oncology announced the positive final results of its...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price is 9.4% higher at the time of writing following precli...
Read ArticleAt the end of January, the GameStop Corp. (NYSE: GME) share price hit an all-time high of US$483. O...
Read ArticleIn February, ASX fintech stocks were winners, losers and winners again. The benchmark ASX 200 index...
Read ArticleSource: ImageFlow,Shutterstock Summary Momentum investing is a relatively newer approach that p...
Read ArticleSource: schankz, Shutterstock Summary The Australian share market’s outlook appears exciting as...
Read ArticleHot on the heels of yesterday’s gains, Race Oncology Ltd (ASX: RAC) shares were marching higher aga...
Read ArticleRace Oncology (ASX:RAC) has released further interim results from its continuing collaborati...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price rocketed 20.98% today, closing the day at $2.48 per sh...
Read ArticleInvex Therapeutics (ASX: IXC) is aiming to hit some significant milestones in 2021 in its bid to use...
Read ArticleSummary The intensity of adoption of tech-enabled health solutions has shot up amidst government...
Read ArticleThe rebound in the S&P/ASX 200 Index (Index:^AXJO) might be grabbing headlines with its dramati...
Read ArticleShareCafeHidden Gems Webinar Recap – OSP, PYG, AGC, RAC Catch up on the full webinar with presentat...
Read ArticleShareCafeRace Oncology Limited (ASX:RAC) – Hidden Gems Webinar Presentation Presenter – Dr Daniel T...
Read ArticleAt time of writing the RAC share price is trading at $2.12 up 7.07%. Race Oncology Ltd (ASX:RAC) ann...
Read ArticleRace Oncology (ASX: RAC) has shared the results of the preclinical research program it is un...
Read ArticleASX-listed oncology drug developer Race Oncology Limited (ASX:RAC) today updated the market with its...
Read ArticleRace Oncology (ASX: RAC) has unveiled what it describes as “impressive” results in preclinical breas...
Read ArticleSummary Race Oncology announced that its Phase 2 clinical trial data of bisantrene had been publi...
Read ArticleWith biotechnology in focus in 2020, Race Oncology is attracting investor interest. -2020 booming ti...
Read ArticleRace Oncology (ASX:RAC) has announced it has secured a new patent on its cancer drug, bisant...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleCancer has long been one of the great evils of healthcare. It is easily one of the most insidious an...
Read ArticleA quick wrap of the key winners and losers on Tuesday, June 16. Data is taken after the market close...
Read ArticleSpecialty pharmaceutical company Race Oncology (ASX: RAC) has reported positive data from an investi...
Read ArticleThe Race Oncology Ltd (ASX: RAC) share price has shot out of the gates this morning on the back of...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleThe journey of each individual medical treatment from idea to market requires the involvement of mul...
Read ArticleThe perception of cancer as one incurable disease is wrong, according to a director of one of the AS...
Read ArticlePre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy acco...
Read ArticleDespite March being a tough month to raise capital for ASX small caps, the money was still flowing f...
Read ArticlePharmaceutical company Race Oncology (ASX: RAC) has come out of a trading halt this morning to annou...
Read ArticleBusinesses will take any opportunity to cash in on a crisis and the latest move to profit from the c...
Read ArticleWith the health and life science sector being the ASX’s top performer last year, Western Australia i...
Read ArticleRace Oncology (RAC) has updated the market on its activities for the December 2019 quarter The comp...
Read ArticleThe health sector was the most successful sector on the ASX in 2019. Various small caps made several...
Read ArticleEvery week Stockhead publishes a weekly column of directors trades of $100,000 or more among ASX sma...
Read ArticleStockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picki...
Read ArticleLast week was another quiet week among directors trades but a handful still made big trades (above $...
Read ArticleRace Oncology (ASX: RAC) has appointed Nucleics founder Dr Daniel Tillett to its board as chief scie...
Read ArticleLast week appeared to be a good time to buy, judging by the number of trades above $100,000; but two...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX small cap health stocks. We last checked in...
Read ArticleDigital healthcare service has evolved as one of the fastest-growing industries in the modern era. I...
Read ArticleThe funding will be used to advance clinical projects for Race’s cancer drug Bisantrene.
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleRace Oncology (ASX:RAC) has announced the successful completion of a $1.45 million placement...
Read ArticleOn Stockhead today, the disconnect between federal and state governments on coal, private equity dea...
Read ArticleOn Stockhead today, investors should fall back in love with junior explorers once tech and cannabis...
Read ArticleA one-day gain of 148 per cent has Opthea as comfortably the best-performing small cap health or bio...
Read ArticleRare cancers can hurt every bit as much as more common cancers, but as it happens, they’re often too...
Read ArticleThe pharmaceutical market in Australia is defined as a knowledge-intensive, technology-driven indust...
Read ArticleRemember Orthocell (ASX: OCC), that company gained 377 per cent in a day when it showed Cel-Gro help...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read Article“This is a major milestone for Race, because it’s the first treatment with Bisantrene since...
Read ArticleIn this week’s recap of substantial holder movements four substantial holders bought shares in Zenit...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
